Baylor Clinic — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$31,487	3
2022	Research	$5,007	3
2021	Research	$6,338	2
2020	Research	$25,970	1
2019	Research	$37,405	9

Breakdown

Who paid Research payments · program years 2019–2023

Merck Sharp & Dohme Corporation $48,755 14 payments
Bausch Health US, LLC $31,052 2 payments
Novartis Pharmaceuticals Corporation $26,400 2 payments

Studies the money was for Research payments · program years 2019–2023

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $31,052 2 payments
A Randomized, Double-Blind, Placebo-Controlled Phase II Multi-Center Study of Intravenous Mbg453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (MDS) As Per Ipss-R Criteria (Stimulus-MD $26,400 2 payments
A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma $21,723 2 payments
A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma $18,619 4 payments
A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair Deficient dMMR Stage IV Colorectal Carcinoma KEYNOTE-177 $4,857 2 payments
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy $3,365 3 payments
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy $96 1 payment
A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma $95 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.